Safety pharmacology - Current and emerging concepts

Toxicology and Applied Pharmacology

Volumn 273, Issue 2, 2013, Pages 229-241

  Hamdam, Junnat ^a   Sethu, Swaminathan ^a   Smith, Trevor ^a   Alfirevic, Ana ^a   Alhaidari, Mohammad ^a   Atkinson, Jeffrey ^b   Ayala, Mimieveshiofuo ^a   Box, Helen ^a   Cross, Michael ^a   Delaunois, Annie ^c   Dermody, Ailsa ^a   Govindappa, Karthik ^a   Guillon, Jean Michel ^d   Jenkins, Rosalind ^a   Kenna, Gerry ^e   Lemmer, Björn ^f   Meecham, Ken ^g   Olayanju, Adedamola ^a   Pestel, Sabine ^h   Rothfuss, Andreas ⁱ   Sidaway, James ^e   Sison Young, Rowena ^a   Smith, Emma ^a   Stebbings, Richard ^j   Tingle, Yulia ^a   Valentin, Jean Pierre ^e   Williams, Awel ^a   Williams, Dominic ^a   Park, Kevin ^a   Goldring, Christopher ^a   more..

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITÉ DE LORRAINE   (France)

^c UCB PHARMA   (Belgium)

^d SANOFI   (France)

^e ASTRAZENECA   (United Kingdom)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g HUNTINGDON LIFE SCIENCES   (United Kingdom)

^h BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

ⁱ National Institute for Biological Standards and Control ^*

^j NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

more..

Author keywords

Cardiovascular; Central nervous system; International Conference on Harmonisation; Respiratory; Risk; Safety pharmacology

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BETA 2 MICROGLOBULIN; CALGRANULIN; CITRULLINE; CLUSTERIN; CREATININE; CYSTATIN C; DIAZEPAM; DIPHENHYDRAMINE; FLUOXETINE; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; GLUTATHIONE TRANSFERASE ALPHA; HEMOGLOBIN; KIDNEY INJURY MOLECULE 1; MICRORNA; MICRORNA 194; MORPHINE; N ACETYL BETA GLUCOSAMINIDASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PENTETRAZOLE; POTASSIUM CHANNEL HERG; PROTEIN; TERFENADINE; TREFOIL PEPTIDE; UNCLASSIFIED DRUG; UREA;

ADVERSE OUTCOME; AIRWAY RESISTANCE; AROUSAL; ATAXIA; BODY PLETHYSMOGRAPHY; BODY POSTURE; BRAIN SLICE; BREATHING; BREATHING RATE; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; CONVULSION; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DIARRHEA; DRUG DISCRIMINATION; DRUG FATALITY; DRUG SAFETY; DRUG SELF ADMINISTRATION; ELECTROENCEPHALOGRAPHY; EYELID REFLEX; FOLLOW UP; GAIT; GASTROINTESTINAL ENDOSCOPY; GLOMERULUS FILTRATION RATE; GLUCOSE URINE LEVEL; GRIP STRENGTH; GROOMING; HEART ARRHYTHMIA; HIPPOCAMPUS; HISTOPATHOLOGY; HUMAN; INTESTINE MOTILITY; KIDNEY CLEARANCE; KIDNEY FUNCTION; LACRIMATION; LOOSE FECES; LUNG ARTERY PRESSURE; LUNG COMPLIANCE; LUNG RESISTANCE; MICTURITION; MUSCLE TONE; NAUSEA; NEUROLOGIC EXAMINATION; NEWBORN DISEASE; NONHUMAN; OSCILLOMETRY; OXYGEN SATURATION; PATCH CLAMP; PLETHYSMOGRAPHY; PNEUMOTACHYGRAPHY; PROTEIN URINE LEVEL; PULMONARY HYPERTENSION; PUPIL REFLEX; QT PROLONGATION; RECTUM TEMPERATURE; REFLEX; RESPIRATORY SYSTEM; REVIEW; RISK ASSESSMENT; SALIVATION; SEDATION; SERUM OSMOLALITY; SHIVERING; SIDE EFFECT; STARTLE REFLEX; STEREOTYPY; STOMACH EMPTYING; STOMACH SECRETION; TELEMETRY; TIDAL VOLUME; TREMOR; UREA NITROGEN BLOOD LEVEL; URINARY TRACT; URINE LEVEL; URINE OSMOLALITY; VOCALIZATION;

Β-NAG; Γ-GLUTAMYL TRANSFERASE; ACTION POTENTIAL; ACUTE KIDNEY INJURY; ADR; ADVERSE DRUG REACTION; AKI; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALP; ALT; AP; ASPARTATE AMINOTRANSFERASE; AST; BLOOD PRESSURE; BLOOD UREA NITROGEN; BP; BUN; CARDIOVASCULAR; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM; CLU; CLUSTERIN; CNS; CVS; ECG; EEG; ELECTROCARDIOGRAM; ELECTROENCEPHALOGRAPHY; EMA; EUROPEAN MEDICINES AGENCY; FDA; FOB; FOOD AND DRUG ADMINISTRATION; FUNCTIONAL OBSERVATION BATTERY; GASTROINTESTINAL; GFR; GGT; GI; GLOMERULAR FILTRATION RATE; GLUTATHIONE S TRANSFERASE; GST; HEART RATE; HERG; HESC; HR; HUMAN EMBRYONIC STEM CELLS; HUMAN ETHER-A-GO-GO RELATED GENE; ICH; INTERNATIONAL CONFERENCE ON HARMONISATION; KIDNEY INJURY MOLECULE-1; KIM-1; LACTATE DEHYDROGENASE; LDH; MICRORNA; MIR; N-ACETYL-Β-D-GLUCOSAMINIDASE; NCE; NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN; NEW CHEMICAL ENTITY; NGAL; NMR; NUCLEAR MAGNETIC RESONANCE; PBPK; PEB; PHOTOELECTRIC BEAM INTERRUPTION TECHNIQUE; PHYSIOLOGICALLY BASED PHARMACOKINETICS; RENAL PAPILLARY ANTIGEN-1; RESPIRATORY; RISK; RPA-1; SAFETY PHARMACOLOGY; SP; TFF3; TREFOIL FACTOR 3; VENTILATION (V)/PERFUSION (Q) MISMATCH (M); VQM;

ANIMALS; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 84888204817     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2013.04.039     Document Type: Review

References (106)

1. Adler A., Cieslewicz G., Irvin C.G. Unrestrained plethysmography is an unreliable measure of airway responsiveness in BALB/c and C57BL/6 mice. J. Appl. Physiol. 2004, 97:286-292.
2. Ali S., Champagne D.L., Spaink H.P., Richardson M.K. Zebrafish embryos and larvae: a new generation of disease models and drug screens. Birth Defects Res. C Embryo Today 2011, 93:115-133.
3. Amen E.M., Becker E.M., Truebel H. Analysis of V/Q-matching-a safety "biomarker" in pulmonary drug development?. Biomarkers 2011, 16(Suppl. 1):S5-S10.
4. Ator N.A., Griffiths R.R. Principles of drug abuse liability assessment in laboratory animals. Drug Alcohol Depend. 2003, 70:S55-S72.
5. Authier S., Legaspi M., Gauvin D., Chaurand F., Fournier S., Troncy E. Validation of respiratory safety pharmacology models: conscious and anesthetized beagle dogs. J. Pharmacol. Toxicol. Methods 2008, 57:52-60.
6. Authier S., Paquette D., Gauvin D., Sammut V., Fournier S., Chaurand F., Troncy E. Video-electroencephalography in conscious non human primate using radiotelemetry and computerized analysis: refinement of a safety pharmacology model. J. Pharmacol. Toxicol. Methods 2009, 60:88-93.
7. Authier S., Haefner P., Fournier S., Troncy E., Moon L.B. Combined cardiopulmonary assessments with implantable telemetry device in conscious freely moving cynomolgus monkeys. J. Pharmacol. Toxicol. Methods 2010, 62:6-11.
8. Bankstahl M., Bankstahl J.P., Bloms-Funke P., Loscher W. Striking differences in proconvulsant-induced alterations of seizure threshold in two rat models. Neurotoxicology 2012, 33:127-137.
9. Barros T.P., Alderton W.K., Reynolds H.M., Roach A.G., Berghmans S. Zebrafish: an emerging technology for in vivo pharmacological assessment to identify potential safety liabilities in early drug discovery. Br. J. Pharmacol. 2008, 154:1400-1413.
10. Bass A.S., Vargas H.M., Kinter L.B. Introduction to nonclinical safety pharmacology and the safety pharmacology society. J. Pharmacol. Toxicol. Methods 2004, 49:141-144.
11. Bass A.S., Vargas H.M., Valentin J.P., Kinter L.B., Hammond T., Wallis R., Siegl P.K., Yamamoto K. Safety pharmacology in 2010 and beyond: survey of significant events of the past 10years and a roadmap to the immediate-, intermediate- and long-term future in recognition of the tenth anniversary of the Safety Pharmacology Society. J. Pharmacol. Toxicol. Methods 2011, 64:7-15.
12. Bates J.H., Thompson-Figueroa J., Lundblad L.K., Irvin C.G. Unrestrained video-assisted plethysmography: a noninvasive method for assessment of lung mechanical function in small animals. J. Appl. Physiol. 2008, 104:253-261.
13. Boudonck K.J., Rose D.J., Karoly E.D., Lee D.P., Lawton K.A., Lapinskas P.J. Metabolomics for early detection of drug-induced kidney injury: review of the current status. Bioanalysis 2009, 1:1645-1663.
14. Bowes J., Brown A.J., Hamon J., Jarolimek W., Sridhar A., Waldron G., Whitebread S. Reducing safety-related drug attrition: the use of in vitro pharmacological profiling. Nat. Rev. Drug Discov. 2012, 11:909-922.
15. Claude J.R., Claude N. Safety pharmacology: an essential interface of pharmacology and toxicology in the non-clinical assessment of new pharmaceuticals. Toxicol. Lett. 2004, 151:25-28.
16. Costa D.L., R J.A., Tepper J.S. Comparative respiratory physiology of the lung 1992, CRC press, Boca Raton.
17. Couderc J.P., Xiaojuan X., Zareba W., Moss A.J. Assessment of the stability of the individual-based correction of QT interval for heart rate. Ann. Noninvasive Electrocardiol. 2005, 10:25-34.
18. Curran M.E., Splawski I., Timothy K.W., Vincent G.M., Green E.D., Keating M.T. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995, 80:795-803.
19. Delaunois A., Dedoncker P., Hanon E., Guyaux M. Repeated assessment of cardiovascular and respiratory functions using combined telemetry and whole-body plethysmography in the rat. J. Pharmacol. Toxicol. Methods 2009, 60:117-129.
20. Dieterle F., Sistare F., Goodsaid F., Papaluca M., Ozer J.S., Webb C.P., Baer W., Senagore A., Schipper M.J., Vonderscher J., Sultana S., Gerhold D.L., Phillips J.A., Maurer G., Carl K., Laurie D., Harpur E., Sonee M., Ennulat D., Holder D., Andrews-Cleavenger D., Gu Y.Z., Thompson K.L., Goering P.L., Vidal J.M., Abadie E., Maciulaitis R., Jacobson-Kram D., Defelice A.F., Hausner E.A., Blank M., Thompson A., Harlow P., Throckmorton D., Xiao S., Xu N., Taylor W., Vamvakas S., Flamion B., Lima B.S., Kasper P., Pasanen M., Prasad K., Troth S., Bounous D., Robinson-Gravatt D., Betton G., Davis M.A., Akunda J., McDuffie J.E., Suter L., Obert L., Guffroy M., Pinches M., Jayadev S., Blomme E.A., Beushausen S.A., Barlow V.G., Collins N., Waring J., Honor D., Snook S., Lee J., Rossi P., Walker E., Mattes W. Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium. Nat. Biotechnol. 2010, 28:455-462.
21. Dunlop J., Bowlby M., Peri R., Vasilyev D., Arias R. High-throughput electrophysiology: an emerging paradigm for ion-channel screening and physiology. Nat. Rev. Drug Discov. 2008, 7:358-368.
22. Durmuller N., Guillaume P., Lacroix P., Porsolt R.D., Moser P. The use of the dog electroencephalogram (EEG) in safety pharmacology to evaluate proconvulsant risk. J. Pharmacol. Toxicol. Methods 2007, 56:234-238.
23. Easter A., Sharp T.H., Valentin J.P., Pollard C.E. Pharmacological validation of a semi-automated in vitro hippocampal brain slice assay for assessment of seizure liability. J. Pharmacol. Toxicol. Methods 2007, 56:223-233.
24. EMA Guideline on the non-clinical investigation of the dependence potential of medicinal products (pp.). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003360.pdf.
25. EMA Guidance for Industry: Drug Interaction Studies - Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations (pp.). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129606.pdf.
26. Emeigh Hart S.G. Assessment of renal injury in vivo. J. Pharmacol. Toxicol. Methods 2005, 52:30-45.
27. FDA ICH S7A Safety Pharmacology Studies for Human Pharmaceuticals (pp.). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm074959.pdf.
28. FDA S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals (pp.). http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm129122.pdf.
29. FDA Guidance for Industry: Assessment of Abuse Potential of Drugs http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM198650.pdf.
30. Froger-Colleaux C., Rompion S., Guillaume P., Porsolt R.D., Castagne V., Moser P. Continuous evaluation of drug withdrawal in the rat using telemetry: effects of morphine and chlordiazepoxide. J. Pharmacol. Toxicol. Methods 2011, 64:81-88.
31. Fuchs T.C., Hewitt P. Biomarkers for drug-induced renal damage and nephrotoxicity-an overview for applied toxicology. AAPS J. 2011, 13:615-631.
32. Fung M., T.Anna, Mybeck Kathy, Hsiao-Hui Jasmanda, Hornbuckle Ken, Muniz Edmundo Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets - 1960 to 1990. Drug Inf. J. 2001, 35:293-317.
33. Gacsalyi U., Zabielski R., Pierzynowski S.G. Telemetry facilitates long-term recording of gastrointestinal myoelectrical activity in pigs. Exp. Physiol. 2000, 85:239-241.
34. Gauvin D.V., Yoder J.D., Dalton J.A., Baird T.J. Comparisons of 3 plethysmography techniques for rodent pulmonary function assessment using ponemah waveforms analysis. J. Pharmacol. Toxicol. Methods 2010, 62:e32-e33.
35. Glennon R.A. Arylalkylamine drugs of abuse: an overview of drug discrimination studies. Pharmacol. Biochem. Behav. 1999, 64:251-256.
36. Globig S., Witte K., Lemmer B. Urinary excretion of nitric oxide, cyclic GMP, and catecholamines during rest and activity period in transgenic hypertensive rats. Chronobiol. Int. 1999, 16:305-314.
37. Goineau S., Rompion S., Guillaume P., Picard S. Ventilatory function assessment in safety pharmacology: optimization of rodent studies using normocapnic or hypercapnic conditions. Toxicol. Appl. Pharmacol. 2010, 247:191-197.
38. Grant A.O. Cardiac ion channels. Circ. Arrhythm. Electrophysiol. 2009, 2:185-194.
39. Guth B.D., Rast G. Dealing with hERG liabilities early: diverse approaches to an important goal in drug development. Br. J. Pharmacol. 2010, 159:22-24.
40. Guth B.D., Bass A.S., Briscoe R., Chivers S., Markert M., Siegl P.K., Valentin J.P. Comparison of electrocardiographic analysis for risk of QT interval prolongation using safety pharmacology and toxicological studies. J. Pharmacol. Toxicol. Methods 2009, 60:107-116.
41. Hancox J.C., McPate M.J., El Harchi A., Zhang Y.H. The hERG potassium channel and hERG screening for drug-induced torsades de pointes. Pharmacol. Ther. 2008, 119:118-132.
42. Harrison A.P., Erlwanger K.H., Elbrond V.S., Andersen N.K., Unmack M.A. Gastrointestinal-tract models and techniques for use in safety pharmacology. J. Pharmacol. Toxicol. Methods 2004, 49:187-199.
43. Hayashi E., Kobayashi T., Shiroshita Y., Kuratani K., Kinoshita M., Hara H. An automated evaluation system for analyzing antinociceptive effects on intracolonic capsaicin-induced visceral pain-related licking behavior in mice. J. Pharmacol. Toxicol. Methods 2011, 64:119-123.
44. Hernandez S.H., Nelson L.S. Prescription drug abuse: insight into the epidemic. Clin. Pharmacol. Ther. 2010, 88:307-317.
45. Hollo Z., Homolya L., Davis C.W., Sarkadi B. Calcein accumulation as a fluorometric functional assay of the multidrug transporter. Biochim. Biophys. Acta 1994, 1191:384-388.
46. Hoymann H.G. Invasive and noninvasive lung function measurements in rodents. J. Pharmacol. Toxicol. Methods 2007, 55:16-26.
47. Hoymann H.G. Lung function measurements in rodents in safety pharmacology studies. Front. Pharmacol. 2012, 3:156.
48. Irwin S. Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse. Psychopharmacologia 1968, 13:222-257.
49. John-Baptiste A., Huang W., Kindt E., Wu A., Vitsky A., Scott W., Gross C., Yang A.H., Schaiff W.T., Ramaiah S.K. Evaluation of potential gastrointestinal biomarkers in a PAK4 inhibitor-treated preclinical toxicity model to address unmonitorable gastrointestinal toxicity. Toxicol. Pathol. 2012.
50. Kaczorowski G.J., Garcia M.L., Bode J., Hess S.D., Patel U.A. The importance of being profiled: improving drug candidate safety and efficacy using ion channel profiling. Front. Pharmacol. 2011, 2:78.
51. Kagstrom J., Sjogren E.L., Ericson A.C. Evaluation of the guinea pig monophasic action potential (MAP) assay in predicting drug-induced delay of ventricular repolarisation using 12 clinically documented drugs. J. Pharmacol. Toxicol. Methods 2007, 56:186-193.
52. Kamendi H.W., Brott D.A., Chen Y., Litwin D.C., Lengel D.J., Fonck C., Bui K.H., Gorko M.A., Bialecki R.A. Combining radio telemetry and automated blood sampling: a novel approach for integrative pharmacology and toxicology studies. J. Pharmacol. Toxicol. Methods 2010, 62:30-39.
53. Kearney K., Metea M., Gleason T., Edwards T., Atterson P. Evaluation of respiratory function in freely moving Beagle dogs using implanted impedance technology. J. Pharmacol. Toxicol. Methods 2010, 62:119-126.
54. Kramer K., Kinter L.B. Evaluation and applications of radiotelemetry in small laboratory animals. Physiol. Genomics 2003, 13:197-205.
55. Kramer J.A., Sagartz J.E., Morris D.L. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. Nat. Rev. Drug Discov. 2007, 6:636-649.
56. Kraushaar U., Meyer T., Hess D., Gepstein L., Mummery C.L., Braam S.R., Guenther E. Cardiac safety pharmacology: from human ether-a-gogo related gene channel block towards induced pluripotent stem cell based disease models. Expert Opin. Drug Saf. 2012, 11:285-298.
57. Laverty H., Benson C., Cartwright E., Cross M., Garland C., Hammond T., Holloway C., McMahon N., Milligan J., Park B., Pirmohamed M., Pollard C., Radford J., Roome N., Sager P., Singh S., Suter T., Suter W., Trafford A., Volders P., Wallis R., Weaver R., York M., Valentin J. How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?. Br. J. Pharmacol. 2011, 163:675-693.
58. Lawrence C.L., Bridgland-Taylor M.H., Pollard C.E., Hammond T.G., Valentin J.P. A rabbit Langendorff heart proarrhythmia model: predictive value for clinical identification of Torsades de Pointes. Br. J. Pharmacol. 2006, 149:845-860.
59. Lemmer B., Mattes A., Bohm M., Ganten D. Circadian blood pressure variation in transgenic hypertensive rats. Hypertension 1993, 22:97-101.
60. Levi F., Hrushesky W.J., Borch R.F., Pleasants M.E., Kennedy B.J., Halberg F. Cisplatin urinary pharmacokinetics and nephrotoxicity: a common circadian mechanism. Cancer Treat. Rep. 1982, 66:1933-1938.
61. Lienemann K., Plotz T., Pestel S. NMR-based urine analysis in rats: prediction of proximal tubule kidney toxicity and phospholipidosis. J. Pharmacol. Toxicol. Methods 2008, 58:41-49.
62. Lindgren S., Bass A.S., Briscoe R., Bruse K., Friedrichs G.S., Kallman M.J., Markgraf C., Patmore L., Pugsley M.K. Benchmarking safety pharmacology regulatory packages and best practice. J. Pharmacol. Toxicol. Methods 2008, 58:99-109.
63. Litwin D.C., Lengel D.J., Kamendi H.W., Bialecki R.A. An integrative pharmacological approach to radio telemetry and blood sampling in pharmaceutical drug discovery and safety assessment. Biomed. Eng. Online 2011, 10:5.
64. Luft J., Bode G. Integration of safety pharmacology endpoints into toxicology studies. Fundam. Clin. Pharmacol. 2002, 16:91-103.
65. Lynch J.J., Castagne V., Moser P.C., Mittelstadt S.W. Comparison of methods for the assessment of locomotor activity in rodent safety pharmacology studies. J. Pharmacol. Toxicol. Methods 2011, 64:74-80.
66. Malik M., Farbom P., Batchvarov V., Hnatkova K., Camm A.J. Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval. Heart 2002, 87:220-228.
67. McGrath P., Li C.Q. Zebrafish: a predictive model for assessing drug-induced toxicity. Drug Discov. Today 2008, 13:394-401.
68. McMahon C., Mitchell A.Z., Klein J.L., Jenkins A.C., Sarazan R.D. Evaluation of blood pressure measurement using a miniature blood pressure transmitter with jacketed external telemetry in cynomolgus monkeys. J. Pharmacol. Toxicol. Methods 2010, 62:127-135.
69. Meyer O., Jenni R., Greiter-Wilke A., Breidenbach A., Holzgrefe H.H. Comparison of telemetry and high-definition oscillometry for blood pressure measurements in conscious dogs: effects of torcetrapib. J. Am. Assoc. Lab. Anim. Sci. 2010, 49:464-471.
70. Miller D.S. Xenobiotic export pumps, endothelin signaling, and tubular nephrotoxicants-a case of molecular hijacking. J. Biochem. Mol. Toxicol. 2002, 16:121-127.
71. Monahan B.P., Ferguson C.L., Killeavy E.S., Lloyd B.K., Troy J., Cantilena L.R. Torsades de pointes occurring in association with terfenadine use. JAMA 1990, 264:2788-2790.
72. Moretti A., Bellin M., Welling A., Jung C.B., Lam J.T., Bott-Flugel L., Dorn T., Goedel A., Hohnke C., Hofmann F., Seyfarth M., Sinnecker D., Schomig A., Laugwitz K.L. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N. Engl. J. Med. 2010, 363:1397-1409.
73. Moscardo E., McPhie G., Fasdelli N., Giarola A., Tontodonati M., Dorigatti R., Meecham K. An integrated cardiovascular and neurobehavioural functional assessment in the conscious telemetered cynomolgus monkey. J. Pharmacol. Toxicol. Methods 2010, 62:95-106.
74. Moser P., Wolinsky T., Castagne V., Duxon M. Current approaches and issues in non-clinical evaluation of abuse and dependence. J. Pharmacol. Toxicol. Methods 2011, 63:160-167.
75. Muller P.Y., Dieterle F. Tissue-specific, non-invasive toxicity biomarkers: translation from preclinical safety assessment to clinical safety monitoring. Expert Opin. Drug Metab. Toxicol. 2009, 5:1023-1038.
76. Murphy D.J. Assessment of respiratory function in safety pharmacology. Fundam. Clin. Pharmacol. 2002, 16:183-196.
77. Murphy D.J., Renninger J.P., Schramek D. Respiratory inductive plethysmography as a method for measuring ventilatory parameters in conscious, non-restrained dogs. J. Pharmacol. Toxicol. Methods 2010, 62:47-53.
78. Nattel S., Carlsson L. Innovative approaches to anti-arrhythmic drug therapy. Nat. Rev. Drug Discov. 2006, 5:1034-1049.
79. Ninkovic J., Bally-Cuif L. The zebrafish as a model system for assessing the reinforcing properties of drugs of abuse. Methods 2006, 39:262-274.
80. Nirogi R., Shanmuganathan D., Jayarajan P., Abraham R., Kancharla B. Comparison of whole body and head out plethysmography using respiratory stimulant and depressant in conscious rats. J. Pharmacol. Toxicol. Methods 2012, 65:37-43.
81. Peng S., Lacerda A.E., Kirsch G.E., Brown A.M., Bruening-Wright A. The action potential and comparative pharmacology of stem cell-derived human cardiomyocytes. J. Pharmacol. Toxicol. Methods 2010, 61:277-286.
82. Pestel S., Martin H.J., Maier G.M., Guth B. Effect of commonly used vehicles on gastrointestinal, renal, and liver function in rats. J. Pharmacol. Toxicol. Methods 2006, 54:200-214.
83. Pestel S., Krzykalla V., Weckesser G. Measurement of glomerular filtration rate in the conscious rat. J. Pharmacol. Toxicol. Methods 2007, 56:277-289.
84. Pirmohamed M., James S., Meakin S., Green C., Scott A.K., Walley T.J., Farrar K., Park B.K., Breckenridge A.M. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004, 329:15-19.
85. Pons M., Schnecko A., Witte K., Lemmer B., Waterhouse J.M., Cambar J. Circadian rhythms in renal function in hypertensive TGR(mRen-2)27 rats and their normotensive controls. Am. J. Physiol. 1996, 271:R1002-R1008.
86. Porsolt R.D., Lemaire M., Durmuller N., Roux S. New perspectives in CNS safety pharmacology. Fundam. Clin. Pharmacol. 2002, 16:197-207.
87. Porsolt R.D., C.D.Niklaus, Lemaire Martine, Moser Paul, Rous Slyvain, France Charles P. Central Nervous System (CNS) Safety Pharmacology Studies 2006, Springer, Germany.
88. Pugsley M.K., Authier S., Curtis M.J. Principles of safety pharmacology. Br. J. Pharmacol. 2008, 154:1382-1399.
89. Rahma M., Kimura S., Yoneyama H., Kosaka H., Nishiyama A., Fukui T., Abe Y. Effects of furosemide on the tubular reabsorption of nitrates in anesthetized dogs. Eur. J. Pharmacol. 2001, 428:113-119.
90. Redfern W.S., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., Palethorpe S., Siegl P.K., Strang I., Sullivan A.T., Wallis R., Camm A.J., Hammond T.G. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res. 2003, 58:32-45.
91. Redfern W.S., Strang I., Storey S., Heys C., Barnard C., Lawton K., Hammond T.G., Valentin J.P. Spectrum of effects detected in the rat functional observational battery following oral administration of non-CNS targeted compounds. J. Pharmacol. Toxicol. Methods 2005, 52:77-82.
92. Redfern W.S., Waldron G., Winter M.J., Butler P., Holbrook M., Wallis R., Valentin J.P. Zebrafish assays as early safety pharmacology screens: paradigm shift or red herring?. J. Pharmacol. Toxicol. Methods 2008, 58:110-117.
93. Samson N., Dumont S., Specq M.L., Praud J.P. Radio telemetry devices to monitor breathing in non-sedated animals. Respir. Physiol. Neurobiol. 2011, 179:111-118.
94. Shah R.R. Can pharmacogenetics help rescue drugs withdrawn from the market?. Pharmacogenomics 2006, 7:889-908.
95. Shell L., Rozum M., Jortner B.S., Ehrich M. Neurotoxicity of acrylamide and 2,5-hexanedione in rats evaluated using a functional observational battery and pathological examination. Neurotoxicol. Teratol. 1992, 14:273-283.
96. Stonard M.D. Assessment of renal function and damage in animal species. A review of the current approach of the academic, governmental and industrial institutions represented by the Animal Clinical Chemistry Association. J. Appl. Toxicol. 1990, 10:267-274.
97. Talavera J., Kirschvink N., Schuller S., Garreres A.L., Gustin P., Detilleux J., Clercx C. Evaluation of respiratory function by barometric whole-body plethysmography in healthy dogs. Vet. J. 2006, 172:67-77.
98. Tontodonati M., Fasdelli N., Moscardo E., Giarola A., Dorigatti R. A canine model used to simultaneously assess potential neurobehavioural and cardiovascular effects of candidate drugs. J. Pharmacol. Toxicol. Methods 2007, 56:265-275.
99. Trepakova E.S., Koerner J., Pettit S.D., Valentin J.P., Committee H.P.-A. A HESI consortium approach to assess the human predictive value of non-clinical repolarization assays. J. Pharmacol. Toxicol. Methods 2009, 60:45-50.
100. Valentin J.P., Hammond T. Safety and secondary pharmacology: successes, threats, challenges and opportunities. J. Pharmacol. Toxicol. Methods 2008, 58:77-87.
101. Valentin J.P., Bass A.S., Atrakchi A., Olejniczak K., Kannosuke F. Challenges and lessons learned since implementation of the safety pharmacology guidance ICH S7A. J. Pharmacol. Toxicol. Methods 2005, 52:22-29.
102. Valentin J.P., Bialecki R., Ewart L., Hammond T., Leishmann D., Lindgren S., Martinez V., Pollard C., Redfern W., Wallis R. A framework to assess the translation of safety pharmacology data to humans. J. Pharmacol. Toxicol. Methods 2009, 60:152-158.
103. Wallis R.M. Integrated risk assessment and predictive value to humans of non-clinical repolarization assays. Br. J. Pharmacol. 2010, 159:115-121.
104. West R., Gossop M. Overview: a comparison of withdrawal symptoms from different drug classes. Addiction 1994, 89:1483-1489.
105. Wienkers L.C., Heath T.G. Predicting in vivo drug interactions from in vitro drug discovery data. Nat. Rev. Drug Discov. 2005, 4:825-833.
106. Winter M.J., Redfern W.S., Hayfield A.J., Owen S.F., Valentin J.P., Hutchinson T.H. Validation of a larval zebrafish locomotor assay for assessing the seizure liability of early-stage development drugs. J. Pharmacol. Toxicol. Methods 2008, 57:176-187.